Navigation Links
Anesiva to Unveil Zingo(TM) Commercialization Plans

SOUTH SAN FRANCISCO, Oct 4 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it will host a briefing for the investment community to review the company's launch and commercialization plans for Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. The briefing will take place on Friday October 12, 2007 from noon to 1:30 p.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit

Anesiva's management and will review the company's manufacturing and commercialization plans as well as the timeline for the Zingo launch. The meeting will also feature William T. Zempsky, M.D., a pediatric pain specialist and associate professor of Pediatrics and Emergency Medicine at the University of Connecticut School of Medicine, who will discuss clinical experience with Zingo and the role it can play in pediatric medicine.

About Zingo

Zingo is a ready-to-use, single-use, needle-free system that delivers sterile lidocaine powder into the epidermis of the skin and provides topical, local analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in pediatric populations and busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options. In addition to the hospital setting, Zingo may be used in physicians' offices and clinical laboratories. Anesiva also recently completed enrollment of a Phase 3 trial evaluating Zingo in adults with the goal of expanding the label beyond the pediatric population.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
2. Canine Painkiller unveiled by Novartis
3. Skin cancers secrets unveiled
4. Pfizer unveils anti-smoking drug
5. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
6. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
7. Study Unveils New Insight To The Madness Of King George III
8. Bush Unveils Latest Blueprint for Handling Bird Flu Pandemic
9. Rae unveils Health-care Strategy
10. Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development
11. New Health Insurance Scheme for Diabetics Unveiled
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... SPH Analytics today announced the following ... Executive Vice President of Operations, and three Senior Vice Presidents, Robert Davis, David ... company. , Debbie Vereb’s appointment to Executive Vice President of Operations at SPH ...
(Date:10/13/2015)... ... 2015 , ... Curly Hair Solutions® is thrilled to be ... exhibition featuring the newest products and services to hit the market for women. ... excited to unveil their recent partnership with Trade Secrets, a leading Canadian beauty ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory test for bacterial ... of Gynecology and Obstetrics in Vancouver, BC, Canada. , In a ...
(Date:10/13/2015)... ... October 13, 2015 , ... Doulagivers is O'Brien's ... Training and End of Life Doula Training. A Doulagiver is a non-medical ... and emotionally. Based on her #1 International bestselling book Creating Positive Passings ...
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, ... the release of its new Professional Medical Coding and Billing with Applied PCS ... ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... 12, 2015  CME Group,s Center for Innovation ... of Theranos, is the 11 th recipient of the ... revolutionary blood diagnostics company, Theranos , to change health ... a new era of preventive care. CME Group will present ... Conference in Naples, Florida , on ...
(Date:10/12/2015)... 12, 2015 --> ... Review, H2 2015 market research report provides data ... by identifying new targets and MOAs to produce ... . --> . ... across 62 pages, analyzing 6 companies, 8 drug ...
(Date:10/12/2015)... October 12, 2015 --> ... on the global vital signs monitoring devices market in its ... Analysis and Opportunity Assessment 2015-2025." The global vital signs monitoring ... of 9.5% and 9.2% in terms of value and volume, ... FMI offers major insights in detail in this report. ...
Breaking Medicine Technology: